BIIB Biogen Inc.

274.05
+2  (1%)
Previous Close 271.88
Open 271.50
Price To book 4.84
Market Cap 59.18B
Shares 215,951,000
Volume 1,025,839
Short Ratio 1.91
Av. Daily Volume 1,663,480

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 dosing commenced December 2016.
Elenbecestat (E2609) - (MissionAD2)
Alzheimer’s disease
Phase 3 enrollment to be completed mid-2018.
Aducanumab (Aβ mAb) - EMERGE
Alzheimer’s disease
Phase 3 to be initiated in 2017.
BIIB074 (Nav1.7 inhibitor)
Trigeminal Neuralgia
Phase 3 dosing commenced December 2016.
Elenbecestat (E2609) - (MissionAD1)
Alzheimer’s disease
Phase 2b to be initiated 4Q 2017.
Opicinumab (anti-LINGO)
Multiple sclerosis (MS)
Phase 3 enrollment to be completed mid-2018.
Aducanumab (Aβ mAb) - ENGAGE
Alzheimer’s disease
Phase 2b enrollment to be completed 2017.
Natalizumab (α4-integrin inhibitor)
Acute ischemic stroke
Phase 2 initiated 2016.
Raxatrigine - BIIB074 (Nav1.7 inhibitor)
Erythromelagia
Phase 2 initiated 2016.
Raxatrigine - BIIB074 (Nav1.7 inhibitor)
Lumbosacral Radiculopathy
Phase 2 ongoing.
Dapirolizumab pegol (anti-CD40L)
Lupus
Phase 2 dosing commenced October 2016.
BIIB059 (anti-BDCA2)
Lupus
Phase 2 data potentially due late 2017 or early 2018.
BAN2401 (Aβ mAb)
Alzheimer’s disease
Phase 2 to be completed 2017.
BG00011 (STX-100)
Idiopathic pulmonary fibrosis (IPF)
Phase 1/2 data due mid-2017.
XLRS Gene Therapy
X-linked retinoschisis (XLRS)

Latest News

  1. Street Watches To See If $125,000 Drug Boosts Biogen's Results
  2. Biogen Says It's Back and Ready for ‘Highly Active’ Dealmaking
  3. Biogen’s SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
  4. What to expect from biotech
  5. What's in Store for Biogen (BIIB) this Earnings Season?
  6. Innoviva director vote drama hands last-minute loss to Sarissa
  7. Activist Sarissa says Innoviva backed out of proxy settlement deal
  8. Gilead Sciences: Who's Frustrated Now?
  9. Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed
  10. Biogen to unveil new data supporting broad use of infant disease drug
  11. Biogen Highlights Advances from Its Neurology Research Programs and Portfolio of Innovative Medicines at AAN Congress
  12. Biogen to License Alzheimer Candidate from Bristol-Myers
  13. How Biogen's Takeover Prospects Soured In Mere Months
  14. Biogen Snaps Up A 'Rare Find' From BMS: Instinet
  15. Could Bristol's Drug Help Biogen Take AbbVie In Alzheimer's?
  16. Biogen pays $300M to Bristol-Myers for another potential Alzheimer's drug
  17. Biotech Movers: Synergy, Biogen, Insys
  18. Bristol-Myers to license two drugs to Biogen, Roche
  19. Bristol-Myers to get $470 million upfront for license deals with Biogen and Roche
  20. Biogen Licenses Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb